Clinical Trials Logo

Thoracic Tumor clinical trials

View clinical trials related to Thoracic Tumor.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06185062 Recruiting - Pelvic Tumor Clinical Trials

Pelvic Cancer Registry for Online Adapted Radiotherapy

PRoART
Start date: January 1, 2024
Phase:
Study type: Observational [Patient Registry]

This prospective registry-based trial will include patients with pelvic or thoracic tumors with an indication for radiotherapy treated with oART or IGRT. For the primary endpoint and the secondary clinical endpoints, the trial will compare oART versus IGRT, for technical endpoints the trial will compare the real oART scenario with two virtual (hypothetical) control scenarios. Primary endpoint: - 10% reduction in the rate of acute radiotherapy related toxicity (≥ CTCAE II°, v5.0) using oART Secondary endpoints: - Clinical endpoints: Tumor control, late toxicities compared to conventional irradiated patients, quality of life and patient-reported outcomes - Technical endpoints: Target volume, target coverage, dose to organs at risk, anatomical variability score

NCT ID: NCT05189054 Recruiting - Recurrent Cancer Clinical Trials

Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors

Start date: May 1, 2022
Phase:
Study type: Observational

The reirradiation of thoracic tumor is difficult. The possibility of surgery or re course radiotherapy is very small. In the NCCN guideline, only systemic treatment is recommended. However, the effective rate of systemic treatment is low. SBRT has the characteristics of high dose in tumor target area and low dose in surrounding normal tissues. In theory, SBRT is more conducive to the protection of normal tissues and can potentially be used in the salvage treatment of recurrent lesions after radiotherapy. Even so, SBRT is still controversial in the rescue treatment of recurrent lung cancer after radiotherapy, especially for "ultral-central" lesions close to mediastinal structures (such as bronchus, esophagus and large blood vessels), which have a high probability of fatal side effects. However, a few studies on the application of SBRT in the reirradiation for ultral-central lung cancer have shown acceptable safety and efficacy. Generally speaking, there are few studies on SBRT in the treatment of recurrent ultral-central tumor with limited data. The purpose of this study is to further evaluate the efficacy and toxicities of SBRT in the treatment of recurrent ultral-central tumors after radiotherapy.

NCT ID: NCT05053230 Recruiting - Ovarian Cancer Clinical Trials

A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer

IMPROVE
Start date: September 20, 2021
Phase: N/A
Study type: Interventional

The overarching long-term goal of the Integrative Medicine for Patient-reported Outcomes Values and Experience (IMPROVE) research program is to evaluate whether integrating a virtual mind-body programming, Integrative Medicine at Home (IM@Home), will improve patient perceived values, outcomes, and experiences as they undergo systemic cancer treatment such as chemotherapy, immunotherapy, radiotherapy, targeted agents, cytoreductive surgery.